Literature DB >> 10645520

Predicting the risk of jaundice in full-term healthy newborns: a prospective population-based study.

D S Seidman1, Z Ergaz, I Paz, A Laor, S Revel-Vilk, D K Stevenson, R Gale.   

Abstract

OBJECTIVE: The need to recognize infants that are at high risk for developing significant jaundice is apparent in the era of routine early discharge. The aim of the present study was to prospectively determine the ability to predict severe hyperbilirubinemia in term healthy newborns (defined as total serum bilirubin of > 10.0 mg/dl at day 2, > 14.0 mg/dl at day 3, and > 17.0 mg/dl at days 4 and 5 of life).
DESIGN: Prospective study of 1177 healthy term newborns.
SETTING: Two university-affiliated community hospitals in Jerusalem.
RESULTS: Using a multiple logistic regression analysis, neonatal jaundice was best predicted (p < 0.0001) by day 1 serum bilirubin (adjusted odds ratio of 3.1 [per mg/dl] [95% confidence limits of 2.4 to 4.1]) and by a change in serum bilirubin from the first to the second day of life (2.4 [per mg/dl] [1.9 to 3.0]). Maternal blood type 0 (2.9 [1.5 to 5.8]), age (1.1 [per year] [1.0 to 1.2]), schooling (0.8 [per year] [0.7 to 0.9]), and full breastfeeding (0.4 [0.2 to 0.9]) were also associated with jaundice (p < 0.005). Other factors considered in the regression model but not found to be significantly related to jaundice included maternal ethnic origin, smoking, hypertension, diabetes mellitus, intranatal administration of oxytocin, meperidine, anesthesia, premature rupture of the membranes, parity, newborn sex, birth weight, gestational age, presentation. Apgar scores, blood type, hematocrit, cephalohematoma, and history of jaundice in other siblings. A model for predicting neonatal jaundice based on the above factors had a sensitivity of 81.8%, a specificity of 82.9%, a false positive rate of 80.2%, and a false negative rate of 1.1%.
CONCLUSION: Individual risk assessment on discharge in association with day 1 total serum bilirubin is of value in identifying infants at greater risk for neonatal jaundice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10645520     DOI: 10.1038/sj.jp.7200274

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  6 in total

1.  Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control study.

Authors:  Michael W Kuzniewicz; Gabriel J Escobar; Soora Wi; Petra Liljestrand; Charles McCulloch; Thomas B Newman
Journal:  J Pediatr       Date:  2008-03-21       Impact factor: 4.406

2.  Predicting neonatal hyperbilirubinemia using first day serum bilirubin levels.

Authors:  Shivani Randev; Neelam Grover
Journal:  Indian J Pediatr       Date:  2010-01-26       Impact factor: 1.967

3.  Ensemble learning for the early prediction of neonatal jaundice with genetic features.

Authors:  Haowen Deng; Youyou Zhou; Lin Wang; Cheng Zhang
Journal:  BMC Med Inform Decis Mak       Date:  2021-12-01       Impact factor: 2.796

4.  Value of twelfth hour bilirubin level in predicting significant hyperbilirubinemia in preterm infants.

Authors:  Izi Mayer; Tugba Gursoy; Mutlu Hayran; Secil Ercin; Fahri Ovali
Journal:  J Clin Med Res       Date:  2014-03-31

5.  Newborn Metabolic Profile Associated with Hyperbilirubinemia With and Without Kernicterus.

Authors:  Molly E McCarthy; Scott P Oltman; Rebecca J Baer; Kelli K Ryckman; Elizabeth E Rogers; Martina A Steurer-Muller; John S Witte; Laura L Jelliffe-Pawlowski
Journal:  Clin Transl Sci       Date:  2018-10-28       Impact factor: 4.689

6.  Determinants of Neonatal Jaundice among Neonates Admitted to Neonatal Intensive Care Unit in Public General Hospitals of Central Zone, Tigray, Northern Ethiopia, 2019: a Case-Control Study.

Authors:  Guesh Gebreayezgi Asefa; Teklay Guesh Gebrewahid; Hailemariam Nuguse; Mengistu Welday Gebremichael; Merhawi Birhane; Kidane Zereabruk; Teklewoini Mariye Zemicheal; Abrha Hailay; Woldu Aberhe Abrha; Surafel Aregawi Hadera; Areaya Gebreegzabiher Hailu; Brhane Hagos Beyene; Ebud Ayele Dagnazgi; Fsaha Gebretsadkan Tekulu; FissahaTekulu Welay
Journal:  Biomed Res Int       Date:  2020-10-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.